迫切需要改变免疫介导疾病的护理和改善结果，患者继续面临不可接受的结果，如永久性器官损伤, uncontrolled disease activity and even death.1-4
Over recent years, 就正在进行的临床试验而言，免疫学已成为临床研究中增长最快的领域之一，仅次于肿瘤学.5
With a growing presence in Immunology, 澳门在线赌城娱乐打算帮助免疫介导性疾病患者超越症状控制，实现缓解, and one day, cure.
Following the science in immune-driven disease areas
Although clinical research in Immunology is fast-growing, 许多患有免疫介导性疾病的人的需求仍未得到满足，他们无法通过现有疗法实现疾病控制. 3,6,7 通过几十年的研究和对途径水平上免疫驱动疾病潜在驱动因素的科学理解, we aim to unlock the complex nature of the diseases we are targeting, uncovering new treatment approaches and driving earlier intervention.
Our bold ambition in immunology – to make remission a treatment goal
澳门第一赌城在线娱乐将继续跟随科学，进一步解开澳门第一赌城在线娱乐对复杂免疫驱动疾病的理解. 澳门第一赌城在线娱乐在免疫学领域的大胆目标是打破目前的治疗模式，使缓解——而不仅仅是症状管理——成为尽可能多的患者的目标.
Complex autoimmune diseases like lupus, 一种可以影响任何器官并导致疾病活动中常常使人衰弱的疾病, 和免疫介导的炎症性疾病，如嗜酸性肉芽肿病伴多血管炎(EGPA), remain challenging to diagnose and treat, and many patients today do not achieve remission.1,3,8-10 For example, people living with EGPA can often take more than four years to receive a diagnosis, and the path to diagnosis can be even longer (up to six years or more) in lupus.1,11 For patients with lupus, achieving disease control can be particularly challenging, and an estimated 10-15% will die prematurely due to lupus-related complications. 1,8
尽管在系统性红斑狼疮(SLE)和EGPA中引入了最新的治疗策略和新疗法, oral corticosteroid (OCS) use still remains high.2,3,9 Although OCS can improve symptoms, long-term use is associated with poor quality of life and serious side effects, 据估计，50%的SLE患者在诊断后5年内由于自身疾病和现有治疗而出现不可逆的器官损害.3,9,12-14
Remission is a treatment target in guidelines for both SLE and EGPA. 欧洲风湿病协会联盟(EULAR)最近更新的国际SLE治疗建议强调了及时开始治疗以缓解的必要性, which is associated with improved clinical outcomes including reduced organ damage, fewer flares, reduced hospitalisation, reduced mortality and improved health-related quality of life. 8,15,16 修订后的SLE治疗建议建议使用OCS-sparing方法(阈值为每天5 mg或更少)，以显著减少疾病进展并改善患者的生活质量.14
Similarly, EGPA的治疗重点是防止复发和增加缓解时间, as the number of relapses and duration of OCS use are associated with long-term organ damage.17,18 全球EGPA指南将诱导和维持缓解作为治疗目标，并建议将OCS的使用控制在最低限度.19,20
A growing body of evidence is emerging, including examples from other chronic diseases, 这可以进一步为指导方针提供信息，以推动更多地采用OCS节约策略，并使医生能够安全有效地减少患者的OCS.
转变观念和实施最新的治疗建议可以使临床实践更接近其他已经取得成功的疾病领域, and, ultimately, 对慢性免疫驱动疾病患者的长期健康产生重大影响.
You may also like
References
1. Lupus Foundation of America. Lupus facts and statistics. Available at: http://www.lupus.org/resources/lupus-facts-and-statistics [last accessed October 2023].
2. Diane Apostolopoulos, Eric F. Morand, It hasn’t gone away: the problem of glucocorticoid use in lupus remains, Rheumatology, Volume 56, Issue suppl_1, April 2017, Pages i114–i122, http://doi.org/10.1093/rheumatology/kew406 [last accessed October 2023]
3. Bell CF, Blauer-Peterson C, Mao J. 与嗜酸性肉芽肿病合并多血管炎相关的疾病负担和费用:来自美国管理医疗数据库的证据. J Manag Care Spec Pharm. 2021 Sep;27(9):1249-1259. doi: 10.18553/jmcp.2021.21002.
4. American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with Polyangiitis (EGPA). Available at: http://apfed.org/about-ead/eosinophilic-granulomatosis-with-polyangiitis/. [last accessed October 2023].
5. Leven, T, Norton M, Vaidyanathan S., Improving Care in Immune-Mediated Diseases. Accessible at: http://www.bcg.com/publications/2022/improving-research-and-development-in-pharma-industry-for-immune-mediated-diseases [last accessed October 2023].
6. Medscape. Systemic Lupus Erythematosus (SLE). Available at: http://emedicine.medscape.com/article/332244-overview [last accessed October 2023]
7. Olesińska M, et al. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia. 2018; 56 (1): 45-54.
8. Ugarte-Gil MF, et al. 系统性红斑狼疮患者的缓解或低疾病活动度与更好的预后相关:一项系统的文献综述. Lupus Sci Med. 2021;8:e000542. doi: 10.1136/lupus-2021-000542
9. Baldini C, et al. Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheum Dis Clin N Am. 2010:36;527–543.
10. Wechsler ME, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017:376;1921-1932.
11. Moosig F, et al. 基于血管炎中心的管理策略可改善嗜酸性肉芽肿病和多血管炎的预后(Churg-Strauss), EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72:1011-1017
12. Segura BT, et al. 在一个多种族的英国队列中，300例系统性红斑狼疮患者的长期随访损害累积和死亡率. Rheumatol. 2020; 59 (3): 524-533.
13. Ugarte-Gil MF, et al. 糖皮质激素对狼疮相关主要器官损伤发生率的影响:纵向观察性研究的系统文献综述和meta回归分析. Lupus Sci Med. 2021; 8 (1): e000590.
14. Bruce IN, et al. 系统性红斑狼疮患者损伤累积相关因素:来自系统性狼疮国际合作诊所(SLICC)初始队列的结果. Ann Rheum Dis. 2015; 74: 1706-1713
15. Fanouriakis A, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. Published Online First: 12 October 2023. doi: 10.1136/ard-2023-224762.
16. Kandane-Rathnayake R, et al. 系统性红斑狼疮患者的狼疮低疾病活动状态、缓解和死亡风险:一项前瞻性研究, multinational, longitudinal cohort study. Lancet Rheumatol. 2022;4(12):e822-e830.
17. Raffray L, et al. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review. Drugs. 2018 Jun;78(8):809-821
18. Robson J, et al. 糖皮质激素治疗和抗中性粒细胞细胞质抗体相关血管损伤:来自欧洲血管炎研究组试验的长期数据. Rheumatology. 2015 Mar;54(3):471-81
19. Chung SA, et al. 2021年美国风湿病学会/血管炎基金会抗中性粒细胞细胞质抗体相关血管炎管理指南. Arthritis Rheumatol. 2021 Aug;73(8):1366-1383.
20. Hellmich B, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023 Mar:ard-2022-223764
Veeva ID: Z4-59056
Date of preparation: November 2023